News & Media

ADPKD, the fourth leading cause of end-stage renal disease,[i],[ii] is a progressively debilitating genetic disease characterized by the development of fluid-filled cysts in the kidneys[iii]Data from two phase 3 clinical trials showed that JYNARQUE™ (tolvaptan) slowed kidney function decline in adults at risk of rapidly progressing ADPKDJYNARQUE can cause serious and potentially fatal liver

Princeton, New Jersey – In celebration of the vibrant startup community in Austin, TX, Otsuka America Pharmaceutical, Inc. (Otsuka) brought together innovators and startups in a live Pitch Event to spark the next generation of innovation in mental health care. Held at Elevate by Psych Congress, a gathering of up-and-coming leaders in mental health care, the event featured some of the most

Tokyo, Japan and Princeton, New Jersey - Otsuka Pharmaceutical Co., Ltd., and its indirect subsidiary Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), announce that the latter has been awarded a grant for up to US $10 million from the Bill & Melinda Gates Foundation to advance clinical development of Otsuka’s investigational compound to treat tuberculosis (TB),

New collaboration between the tech-enabled clinical research company and US mental health leader aims to transform clinical trials to accelerate patient access to innovative therapies PLAYA VISTA, CA. and ROCKVILLE, MD. (December 5, 2017) – Science 37, a trailblazing company focused on “site-less” clinical trials, and Otsuka Pharmaceutical Development & Commercialization, Inc.